Skip to main content
Premium Trial:

Request an Annual Quote

Jury Awards Promega $52M in Damages in IP Suit with Life Tech


Promega said this week that a jury has ruled in its favor in a patent infringement suit against Life Technologies and awarded it $52 million in damages.

The United States District Court for the Western District of Wisconsin found that Life Tech willfully infringed Promega's patents related to short tandem repeats.

The willfulness verdict means that the court may increase the final damage amount, Promega said.

The company noted that the court has also set a schedule to consider an injunction against Life Technologies for its sale of the infringing products, but did not provide further details.

Promega filed its lawsuit against Life Tech in May 2010. The court issued a summary judgment in November that found Life Tech to be directly infringing Promega's patents with the sale of its own STR kits.

The technology is used for genetic analysis applications including genetic research, cell line authentication, bone marrow transplantation monitoring, forensic training, and cancer analysis.

"Life Technologies is considering its options in light of the verdict … including post-trial motions and appeals," Life Tech said in a statement.

The company added that sales of its STR products for the core forensics and paternity fields are not affected by the verdict.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.